The attack, thought to have involved a juvenile great white which could have been around 4ft (1.2m) in length, took place in the early hours of 30 September.
It left Mr Murray with severe lacerations to his hand and foot, and meant he had to…
Author: admin
-
Pakistan Army organises informative visit of Cholistan university’s students
Students of the Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, undertook an informative and memorable visit organised by the Pakistan Army, during which they received practical…
Continue Reading
-
Sydney New Year’s Eve strikes more sombre tone as fireworks follow minute’s silence for Bondi | Australia news
Australia paused to show solidarity with the Jewish community as New Year’s Eve festivities rolled across the nation.
Weeks on from the Bondi Beach terrorist attack, hundreds of thousands of people around the Sydney Harbour observed a minute’s…
Continue Reading
-
Queen Camilla recalls assault in 1960s as she campaigns against domestic violence
LONDON — LONDON (AP) — Britain ’s Queen Camilla on Wednesday spoke publicly for the first time about her personal experience of indecent assault, saying that speaking out was one way she could use her royal platform to shine a light on the…
Continue Reading
-
10 Conflicts to Watch in 2026 – International Crisis Group
- 10 Conflicts to Watch in 2026 International Crisis Group
- Outlook: Geopolitical Trends and Global Diplomacy in 2026 The Diplomat – Asia-Pacific Current Affairs Magazine
- It’s not just Taiwan… Five flashpoints that could spark World War Three…
Continue Reading
-
EHang EH216-Series eVTOL Aircraft Completes First Cross-Province Flight, Crossing Qiongzhou Strait
Guangzhou, China – December 31, 2025 – EHang Holdings Limited (Nasdaq: EH), a global leader in Advanced Air Mobility (AAM), announced today that its EH216-series pilotless electric vertical takeoff and landing (eVTOL) aircraft has successfully completed a point-to-point flight across the Qiongzhou Strait. The aircraft departed from Nanhai Mingzhu Island in Haikou City, Hainan Province, and arrived at Xuwen Port in Zhanjiang City, Guangdong Province, completing the 22-kilometer journey in just 18 minutes. This represents a significant reduction from the typical 60–90 minutes ferry crossing, improving travel efficiency by approximately 70–80%. This validates the technical capabilities and efficiency of pilotless eVTOLs in over-water operations and lays a solid technological foundation for future coordinated low-altitude mobility development between Hainan and Guangdong Provinces.
Image: EH216-series eVTOL completes a point-to-point flight from Haikou, Hainan to Zhanjiang, Guangdong, crossing the Qiongzhou Strait
The EH216-series aircraft that successfully crossed the strait is equipped with a high-energy solid-state battery co-developed by EHang and its partner Inx Energy. This flight effectively demonstrates the stable performance of this battery in complex environments such as over-water eVTOL operations, providing strong technical support for diverse applications including cross-strait transportation, island tourism, maritime emergency response, and island logistics. It also paves the way for effective inter-provincial connectivity and extends to longer-range flights covering multiple cities within the Guangdong-Hong Kong-Macao Greater Bay Area, enabling inter-city passenger and cargo transport and accelerating the commercialization of the low-altitude economy.
EHang, in collaboration with its partners, has actively conducted application scenario flights under various weather conditions and terrains worldwide. It has accumulated extensive safe flight data in environments exceeding 3,000 meters in altitude, extreme cold and heat, typhoons, rain, snow, and over rivers, lakes, and seas. This experience provided crucial support and assurance for this cross-strait flight. The EHang team completed route planning, weather surveying, and all necessary flight support preparations in the shortest time possible. The aircraft achieved stable flight across the strait under conditions of long distance and rapidly changing winds and waves, showcasing its high-redundancy safety performance and validating the leading capabilities of EHang’s pilotless aircraft.
The flight was witnessed by distinguished guests at the “Soaring Skyward” event series in the Hainan Free Trade Port, including Mr. Dong Zhiyi, Chief Low-Altitude Economy Expert at the Chinese Society of Aeronautics and Astronautics and former Deputy Administrator of the Civil Aviation Administration of China; Mr. Xiao Faxuan, Chairman of Hainan Airport Group; Mr. Luo Hongxia, Secretary of Xuwen County, Zhanjiang City, Guangdong Province; Mr. Liu Libo, Chairman of Pengcheng Low-Altitude Economy Industry Development (Shenzhen) Co., Ltd. and Executive President of the Greater Bay Area Low-Altitude Economy UAV Association; Mr. Wang Dong, Vice President of EHang and General Manager of EHang General Aviation; and Mr. He Tianxing, Vice President of EHang. As the first pilotless human-carrying eVTOL to cross the Qiongzhou Strait, the EH216-series received high praise for its safe and stable performance.
Image: EH216-series eVTOL with the solid-state battery completes a flight, crossing the Qiongzhou Strait
With the Hainan Free Trade Port now fully operational under its special customs regime, a range of tailored low-altitude application scenarios are emerging. These encompass low-altitude passenger transport to alleviate congestion across the Qiongzhou Strait, cross-border logistics to enhance the Port’s circulation efficiency, and cross-strait tourism linking the cultural resources of Hainan and Guangdong.
This EH216-series flight serves not only to validate the technology for these post-customs-closure scenarios but also to establish a potential low-altitude corridor between Hainan and Guangdong. This will further help EHang solidify its development foundation across both provinces, foster international exchange, and cultivate a low-altitude application ecosystem, thereby injecting new momentum into Hainan’s low-altitude economy and the cultivation of new quality productive forces for the Free Trade Port.
Mr. Xiao Faxuan, Chairman of Hainan Airport Group, stated in his address, “EHang’s successful pilotless eVTOL flight across the Qiongzhou Strait is a vivid example of innovative development in Hainan’s low-altitude economy. We will seize the opportunity presented by the Free Trade Port’s special customs operations to build a pioneer zone for low-altitude economy applications, empowering industrial development through practical applications and making the low-altitude economy a new growth engine for the Free Trade Port. We will also deepen collaboration between Hainan Province and Guangdong Province, integrate policy and industrial resources across both provinces, facilitate smooth cross-province air mobility, and unite powerful synergies for low-altitude economy development, thereby infusing greater vitality into the Hainan Free Trade Port.”
Wang Zhao, Chief Operating Officer of EHang, said, “The successful crossing of the Qiongzhou Strait by our EH216-series pilotless eVTOL validates its adaptability and the efficiency gains it brings in complex environments like over-water routes. This achievement is also a significant result of our collaboration with partners to comprehensively enhance core safety performance and jointly build a diverse application ecosystem. Coinciding with the historic opportunity of the Hainan Free Trade Port’s special customs operations, the low-altitude economy—a key emerging sector for the Port—is facing promising growth prospects. EHang will leverage this opportunity to continue empowering diverse applications in Hainan, including long-distance logistics, and emergency response, with our pilotless aircraft technology. We are committed to supporting Hainan in building a national innovation and demonstration hub for the low-altitude economy.
About EHang
EHang (Nasdaq: EH) is the world’s leading advanced air mobility (“AAM”) technology platform company, committed to making safe, autonomous, and eco-friendly air mobility accessible to everyone. The company develops and manufactures a diversified portfolio of pilotless electric vertical take-off and landing (“eVTOL”) aircraft for a wide range of use cases, including aerial tourism, intra-city transport, intercity travel, logistics and emergency firefighting. Its flagship model, EH216-S, has obtained the world’s first type certificate, production certificate and standard airworthiness certificate for pilotless eVTOL issued by the Civil Aviation Administration of China, and is now commercially operated under the country’s first Air Operator Certificates for human-carrying eVTOL services. Complementing this, EHang’s VT35 expands its reach into long-range and intercity scenarios, supporting the development of a multi-tiered low-altitude mobility network. By integrating advanced autonomous technologies with scalable operational infrastructure, EHang is redefining how people and goods move—across cities, regions, and natural barriers—shaping the future of air mobility. For more information, please visit www.ehang.com.
Safe Harbor Statement
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about management’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to those relating to certifications, our expectations regarding demand for, and market acceptance of, our products and solutions and the commercialization of UAM services, our relationships with strategic partners, and current litigation and potential litigation involving us. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause EHang’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
Continue Reading
-
Cancer Misinformation in 2025: How Viral Narratives Are Putting Patients at Risk
In 2025, cancer misinformation did not merely spread faster than facts it reshaped patient behavior, public trust, and clinical outcomes. From a real genetic ethics failure in reproductive medicine to distorted interpretations of…
Continue Reading
-
2011 Chevrolet Camaro 2SS ZTA Trans Am Convertible Blends Modern Performance With Classic Styling
A 2011 Chevrolet Camaro 2SS ZTA Trans Am Convertible is being offered for sale with a listed price of $37,900, presenting a modern interpretation of classic Pontiac Trans Am design cues applied to Chevrolet’s fifth-generation Camaro…
Continue Reading
-
PISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy
Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52, 650–656 (1979).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266–276 (2001).
Michiels, C., Tellier, C. & Feron, O. Cycling hypoxia: A key feature of the tumor microenvironment. Biochim. Biophys. Acta. 1866, 76–86 (2016).
Span, P. N. & Bussink, J. Biology of hypoxia. Semin Nucl. Med. 45, 101–109 (2015).
Tatum, J. L. et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82, 699–757 (2006).
Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 9, 539–549 (1955).
Vaupel, P. & Mayer, A. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv. Exp. Med. Biol. 812, 19–24 (2014).
Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 3, 83–92 (2015).
Rankin, E. B. & Giaccia, A. J. Hypoxic control of metastasis. Science 352, 175–180 (2016).
Rockwell, S., Dobrucki, I. T., Kim, E. Y., Marrison, S. T. & Vu, V. T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr. Mol. Med. 9, 442–458 (2009).
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M. & Toomey, D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29, 297–307 (2003).
Walsh, J. C. et al. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid. Redox Signal. 21, 1516–1554 (2014).
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L. & Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285–289 (1997).
Brown, J. M. The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F. Cain memorial award lecture. Cancer Res. 59, 5863–5870 (1999).
Denny, W. A. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol. 6, 419–428 (2010).
Duan, J. X. et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J. Med. Chem. 51, 2412–2420 (2008).
Hunter, F. W., Wouters, B. G. & Wilson, W. R. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br. J. Cancer. 114, 1071–1077 (2016).
Melillo, G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 26, 341–352 (2007).
Patel, A. & Sant, S. Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotechnol. Adv. 34, 803–812 (2016).
Phillips, R. M. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother. Pharmacol. 77, 441–457 (2016).
Wigerup, C., Pahlman, S. & Bexell, D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 164, 152–169 (2016).
Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer. 11, 393–410 (2011).
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K. & Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239–1242 (1986).
Oostveen, E. A. & Speckamp, W. N. Mitomycin Analogs.1. Indoloquinones as (Potential) bisalkylating agents. Tetrahedron 43, 255–262 (1987).
Patterson, A. V. et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Research: Official J. Am. Association Cancer Res. 13, 3922–3932 (2007).
Nishida, C. R. & de Ortiz, P. R. Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J. Med. Chem. 51, 5118–5120 (2008).
Liu, Q. et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother. Pharmacol. 69, 1487–1498 (2012).
Patterson, A. V. et al. The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a phase 1 clinical trial. Cancer Res. 75 (15_Supplement), 5358 (2015).
Patterson, A. V. et al. TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. J. Clin. Oncol. 33, e13548–e13548 (2015).
Abbattista, M. R. et al. Pre-clinical activity of PR-104 as monotherapy and in combination with Sorafenib in hepatocellular carcinoma. Cancer Biol. Ther. 16, 610–622 (2015).
Benito, J. et al. Hypoxia-Activated prodrug TH-302 targets hypoxic bone marrow niches in preclinical leukemia models. Clin. Cancer Research: Official J. Am. Association Cancer Res. 22, 1687–1698 (2016).
Del Rowe, J. et al. Single-arm, open-label phase II study of intravenously administered Tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 18, 1254–1259 (2000).
Konopleva, M. et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100, 927–934 (2015).
Masunaga, S. et al. Usefulness of combined treatment with continuous administration of Tirapazamine and mild temperature hyperthermia in gamma-ray irradiation in terms of local tumour response and lung metastatic potential. Int. J. Hyperth. 28, 636–644 (2012).
Sun, J. D. et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer Research: Official J. Am. Association Cancer Res. 18, 758–770 (2012).
Groshar, D. et al. Imaging tumor hypoxia and tumor perfusion. J. Nucl. Med. 34, 885–888 (1993).
Lee, C. T., Boss, M. K. & Dewhirst, M. W. Imaging tumor hypoxia to advance radiation oncology. Antioxid. Redox Signal. 21, 313–337 (2014).
Minn, H. et al. Imaging of tumor hypoxia to predict treatment sensitivity. Curr. Pharm. Design. 14, 2932–2942 (2008).
Pacheco-Torres, J., Lopez-Larrubia, P., Ballesteros, P. & Cerdan, S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed. 24, 1–16 (2011).
Reischl, G. et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA–first small animal PET results. J. Pharm. Pharm. Sciences: Publication Can. Soc. Pharm. Sci. Societe Canadienne des. Sci. Pharmaceutiques. 10, 203–211 (2007).
Vaupel, P. & Mayer, A. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid. Redox Signal. 22, 878–880 (2015).
Baudelet, C. & Gallez, B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn. Reson. Med. 48, 980–986 (2002).
Ding, Y. et al. Simultaneous measurement of tissue oxygen level-dependent (TOLD) and blood oxygenation level-dependent (BOLD) effects in abdominal tissue oxygenation level studies. J. Magn. Reson. Imaging. 38, 1230–1236 (2013).
O’Connor, J. P. et al. Oxygen-Enhanced MRI accurately Identifies, Quantifies, and maps tumor hypoxia in preclinical cancer models. Cancer Res. 76, 787–795 (2016).
Gulaka, P. K. et al. GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo. J. Biol. Inorg. Chem. 19, 271–279 (2014).
Rojas-Quijano, F. A. et al. Synthesis and characterization of a hypoxia-sensitive MRI probe. Chemistry 18, 9669–9676 (2012).
Mason, R. P., Rodbumrung, W. & Antich, P. P. Hexafluorobenzene: a sensitive 19F NMR indicator of tumor oxygenation. NMR Biomed. 9, 125–134 (1996).
Kodibagkar, V. D., Cui, W., Merritt, M. E. & Mason, R. P. Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magn. Reson. Med. 55, 743–748 (2006).
Kodibagkar, V. D., Wang, X., Pacheco-Torres, J., Gulaka, P. & Mason, R. P. Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL): a tool for quantitative tissue oximetry. NMR Biomed. 21, 899–907 (2008).
Agarwal, S., Gulaka, P. K., Rastogi, U. & Kodibagkar, V. D. More bullets for PISTOL: linear and Cyclic siloxane reporter probes for quantitative (1)H MR oximetry. Sci. Rep. 10, 1399 (2020).
Hoehn-Berlage, M., Tolxdorff, T., Bockhorst, K., Okada, Y. & Ernestus, R. I. In vivo NMR T2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn. Reson. Imaging. 10, 935–947 (1992).
Zhao, D., Jiang, L. & Mason, R. P. Measuring changes in tumor oxygenation. Methods Enzymol. 386, 378–418 (2004).
Dula, A. N., Gochberg, D. F., Valentine, H. L., Valentine, W. M. & Does, M. D. Multiexponential T2, magnetization transfer, and quantitative histology in white matter tracts of rat spinal cord. Magn. Reson. Med. 63, 902–909 (2010).
Harkins, K. D., Valentine, W. M., Gochberg, D. F. & Does, M. D. In-vivo multi-exponential T2, magnetization transfer and quantitative histology in a rat model of intramyelinic edema. Neuroimage Clin. 2, 810–817 (2013).
Stokes, A. M., Hart, C. P. & Quarles, C. C. Hypoxia imaging with PET correlates with antitumor activity of the Hypoxia-Activated prodrug Evofosfamide (TH-302) in rodent glioma models. Tomography 2, 229–237 (2016).
Takakusagi, Y. et al. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302. PLoS One. 9, e107995 (2014).
Cherk, M. H. et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J. Nucl. Med. 47, 1921–1926 (2006).
Piert, M. et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J. Nucl. Med. 46, 106–113 (2005).
Solomon, B. et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther. 4, 1417–1422 (2005).
Lin, Y., Wang, X. & Jin, H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am. J. Cancer Res. 4, 411–435 (2014).
Choi, K., Creighton, C. J., Stivers, D., Fujimoto, N. & Kurie, J. M. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One. 2, e1226 (2007).
Anderson, N. G., Ahmad, T., Chan, K., Dobson, R. & Bundred, N. J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer. 94, 774–782 (2001).
Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 4, 437–447 (2004).
Wilson, W. R. et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with Dinitrobenzamide mustards. Radiat. Res. 167, 625–636 (2007).
Arvold, N. D., Heidari, P., Kunawudhi, A., Sequist, L. V. & Mahmood, U. Tumor hypoxia response after targeted therapy in EGFR-Mutant Non-Small cell lung cancer: proof of concept for FMISO-PET. Technol. Cancer Res. Treat. 15, 234–242 (2016).
Bains, L. J., Baker, J. H., Kyle, A. H., Minchinton, A. I. & Reinsberg, S. A. Detecting vascular-targeting effects of the hypoxic cytotoxin Tirapazamine in tumor xenografts using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 74, 957–965 (2009).
Baker, J. H. et al. Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS Inhibition by treatment with a hypoxic cytotoxin. PLoS One. 8, e76832 (2013).
Huxham, L. A., Kyle, A. H., Baker, J. H., McNicol, K. L. & Minchinton, A. I. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol. 78, 138–145 (2006).
Huxham, L. A., Kyle, A. H., Baker, J. H., McNicol, K. L. & Minchinton, A. I. Exploring vascular dysfunction caused by Tirapazamine. Microvasc Res. 75, 247–255 (2008).
Continue Reading
-
Trading at PSX turns choppy as investors lock in gains
Trading at the Pakistan Stock Exchange remained choppy on Wednesday as early optimism faded in the face of mounting profit-taking. This volatile performance came after a sustained rally over recent sessions, prompting investors to adopt a cautious stance.
The benchmark KSE-100 index kicked off the session on a bullish footing, racing to an intra-day peak of 175,232.90 and briefly breaching the landmark 175,000-point level for the first time. However, the momentum could not be sustained. As the session progressed, investors chose to lock in gains, prompting a gradual retreat from the day’s highs. As a result, the index slipped to an intra-day low of 173,564.33 amid broad-based selling.
Pressure was most evident in heavyweight sectors such as automobile assemblers, commercial banks, power generation, and refineries, which collectively dragged the market lower. By the close, the KSE-100 index ended in negative territory, shedding 418.47 points, or 0.24%, to settle at 174,054.32.
Meanwhile, the broader market outlook remains constructive despite near-term volatility. The KSE-100 index emerged as the second-best performing frontier market in CY25, delivering a robust 51% return and closing the year at a fresh record high, Arif Habib Limited (AHL) reported.
This performance extends its three-year streak of double-digit gains, following returns of 55% in CY23 and an exceptional 84% in CY24, with only Romania outperforming Pakistan among frontier markets.
Over the past three years, the index has generated an average annual return of 64%, placing it among the top-performing equity markets globally. In dollar terms, cumulative returns reached 249%, a level unmatched by any other market over the same three-year period, AHL wrote.Overall trading volume increased to 957.2million shares compared with Tuesday’s tally of 851milion. Value of traded shares stood at Rs44.2 million. Shares of 481 companies were traded. Of these, 221 closed higher, 223 fell and 37 remained unchanged. K-Electric was the volume topper with trading in 95.9 million shares, gaining Rs0.21 to close at Rs5.93.
Continue Reading